148 related articles for article (PubMed ID: 34791262)
1. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant.
Jha MK
Int J Neuropsychopharmacol; 2022 Jan; 25(1):85-88. PubMed ID: 34791262
[TBL] [Abstract][Full Text] [Related]
2. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
[TBL] [Abstract][Full Text] [Related]
3. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
Transl Psychiatry; 2019 Sep; 9(1):216. PubMed ID: 31481683
[TBL] [Abstract][Full Text] [Related]
4. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
Savitz A; Wajs E; Zhang Y; Xu H; Etropolski M; Thase ME; Drevets WC
Int J Neuropsychopharmacol; 2021 Dec; 24(12):965-976. PubMed ID: 34324636
[TBL] [Abstract][Full Text] [Related]
6. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
Fagan H; Jones E; Baldwin DS
CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
[TBL] [Abstract][Full Text] [Related]
7. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
Connor KM; Ceesay P; Hutzelmann J; Snavely D; Krystal AD; Trivedi MH; Thase M; Lines C; Herring WJ; Michelson D
Int J Neuropsychopharmacol; 2017 Aug; 20(8):613-618. PubMed ID: 28582570
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Seltorexant-Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety.
Ziemichód W; Kurowska A; Grabowska K; Kurowska M; Biała G
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110810
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
11. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
Petrous J; Furmaga K
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
[TBL] [Abstract][Full Text] [Related]
12. Orexin Receptor Antagonists as Adjunct Drugs for the Treatment of Depression: A Mini Meta-Analysis.
Uğurlu M
Noro Psikiyatr Ars; 2024; 61(1):77-84. PubMed ID: 38496221
[TBL] [Abstract][Full Text] [Related]
13. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
[TBL] [Abstract][Full Text] [Related]
14. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
Janto K; Prichard JR; Pusalavidyasagar S
J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
17. New pharmacologic agents for insomnia and hypersomnia.
Earl DC; Van Tyle KM
Curr Opin Pulm Med; 2020 Nov; 26(6):629-633. PubMed ID: 32890017
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
20. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
